-
Featured
Low-risk Incidental Prostate Cancer in Men with Bladder Cancer May Be Associated with Longer Survival
Men with bladder cancer who have low-risk prostate cancer detected incidentally by radical cystoprostatectomy may actually have a more favorable prognosis than those who do not.
-
Featured
Ultrasound Therapy Yields Promising Results for Localized Prostate Cancer
At the American Urological Association's 2019 Annual Meeting, researchers presented the findings of a study on the effects transurethral ultrasound ablation (TULSA), a novel minimally invasive procedure that can reduce prostate size and prostate-specific antigens in patients with localized prostate cancer.
-
Featured
New Target Discovered for Prostate Cancer Immunotherapy
Genitourinary pathologists at Massachusetts General Hospital are the first to demonstrate that PD-L1 expression is highly prevalent in prostate tumor-associated nerves. Such nerves may represent an important target for immunotherapy regimens.
-
Improving Prostate MRI Screening for Genetically High-Risk Individuals
New research with roots at Mass General Brigham Cancer Institute shows that combining age-adjusted PSA thresholds with upfront MRI improves detection of clinically significant prostate cancer in genetically high-risk men—outperforming either test alone.
-
How a Neoadjuvant Microdevice Could Transform Treatment of Prostate Cancer
Mass General Brigham researchers are in the early stages of developing a 3mm implantable chip that delivers micro-doses of drugs directly into prostate tumors prior to planned radical prostatectomy. Analyzing tumor response eventually could help clinicians optimize drug selection for individual patients.
-
Monitoring of PSA Density Advised During Active Surveillance of Prostate Cancer
Adam S. Feldman, MD, MPH, Andrew Gusev, MD, and colleagues, are the first to show that prostate-specific antigen density retains significant prognostic value after diagnosis of prostate cancer, with values ≥0.15 ng/mL2 at any point during active surveillance nearly quadrupling the risk of biopsy grade progression.
Prostate Cancer Contributors
-
Adam S. Feldman, MD, MPH
Director, Combined Harvard Urologic Oncology Fellowship, Associate Chair for Research, Urologic Oncologist, Department of Urology, Massachusetts General Hospital, Associate Professor of Surgery, Harvard Medical School
Recent Article
Monitoring of PSA Density Advised During Active Surveillance of Prostate Cancer
-
Chin-Lee Wu, MD, PhD
Director, Genitourinary Pathology Service, Massachusetts General Hospital and Mass General Brigham Cancer Institute, Professor of Pathology, Harvard Medical School
Recent Article
Multiparametric MRI Is Often False-Negative for Clinically Significant Prostate Cancer
-
Douglas M. Dahl, MD
Chief, Division of Urologic Oncology, Vice-Chair, Department of Urology, Massachusetts General Hospital, Co-Director, The Claire and John Bertucci Center for Genitourinary Cancers, Mass General Brigham Cancer Institute, Associate Professor of Surgery (Urology), Harvard Medical School
Recent Article
Multiparametric MRI Is Often False-Negative for Clinically Significant Prostate Cancer
-
Mass General Bladder, Kidney, Penile, Prostate and Testicular Cancer Program
Physicians in the Mass General Bladder, Kidney, Penile, Prostate and Testicular Cancer Program specialize in using advanced surgical therapies and minimally invasive procedures to treat male and female genitourinary cancers.